IVVD Invivyd Inc

$IVVD it really is a different market. Already given back half of it's gains AH. With that said insts hold almost all of it and they may not be so quick to dump on $.25-$30 move. Some point near term this should reprice moin$3-$4 on positive news. Targets (While don't mean shit in todays world) are in the $10 range. Investors in this company have had a long road, lets hope for some feeling good new and days ahead. 🙏

$IVVD options expired Friday and did anyone else notice a large institution had puts? They also have calls. Let her rip!

$IVVD CEO Mark Elia rocked that conference call. These Liberty results are over the top on all metrics/end points and setup Declaration very nicely. Way oversold and a very nice opportunity to average down and accumulate.

$IVVD for biotech topline clinical data, Monday through Thursday is the normal zone, and Tuesday–Thursday tends to feel especially common. Friday releases happen, but companies generally avoid dropping major market-moving data late Friday unless timing dictates it. For IVVD specifically, their history is actually pretty useful: * Monday: Dec. 18, 2023 — positive CANOPY Phase 3 results; Feb. 3, 2025 — positive VYD2311 Phase 1/2 data. * Tuesday: Nov. 12, 2024 — CANOPY clinical data/preprints; May 27, 2025 — CANOPY publication/data; Feb. 24, 2026 — new clinical analysis. * Thursday: June 26, 2025 — full VYD2311 Phase 1/2 clinical data, released at 7:01 AM ET. * Friday: March 22, 2024 — interim CANOPY exploratory data, so they clearly will use Friday when necessary. Release? Tomorrow Friday: possible, but not my favorite Monday Sept. 28: very plausible Tuesday Sept. 29: probably my favorite Wednesday Sept. 30: extremely plausible because it’s literally the final day of Q3

$IVVD Call and commentary from Elia much more positive than the initial data release. The October DECLARATION update will be critical given the regulatory path chosen, but the accelerated approval strategy appears to have been developed through active FDA engagement, including the type C meeting in Q3. Elia also explicitly confirmed that additional participants will be enrolled in a confirmatory randomized cohort to ensure DECLARATION is sufficiently powered for the eventual clinical efficacy readout

$IVVD Many people look at this wrong. The long term lease agreement is not the catalyst for the jump. But the long term lease is a confirmation that they data they have is good and they are confident to took a long term lease and expanding the office. Thats the catalyst.

$IVVD way oversold on good data but missed the DECLARATION data which are pushed to Oct. Next catalyst: - FDA's official Type C minutes, likely within weeks - DECLARATION data, also within weeks

$IVVD been adding in 70s . Hope to see some good news between now and next year. This investment is a risky one but like the chances here and 3 analyst with $10 targets. Can all 3 analysts be idiots and wrong? It’s possible! Lol

$IVVD is $10 target actually feasible here? Given they need to release data soon but 3 analyst with good ratings actually gave this price target

$IVVD anyone noticed we had some institutional buying into new positions the past couple weeks? 🐂🐂

$IVVD listened to Cantor chat. I’ve listened to my fair share over the years of such presentations and Elia is damn impressive.

$IVVD $2+ on good data, if market starts pricing in the approval, we could see $3+ , Probability of succes: 75%!

$IVVD ,the word is IF ivvd is granted the DECLARATION, the stock is to spike between $1 and 3 dollars, and if the F.D.A approves the vaccine, the stock is to spike between $5 and 8 dollars between 2027 and 2028 if sales for the vaccine is successful. Or a possibility of a buy out.

$IVVD albeit a different CEO at the helm though Mark Elia was part of the equation, so maybe tomorrow…

$IVVD Hit .93+ cents the other day. Just wondering what's going on. I did partly Listen to the chat the other day. I'm holding a small position. GLTA ✌️

$IVVD Wainwright fireside takeaways: CEO says 70-90% VE target and "should be getting" it. New HHS talks for accelerated access. Zero competitors left. Dual BLA pathway = downside protection. $60-70M revenue already growing 25%. This isn't a clinical stage gamble anymore. This is a commercial company trading at 3.5x revenue with a monopoly catalyst weeks away Current product already doing $60-70M run rate growing 25% — and that's the OLD IV antibody before VYD2311 even launches

$IVVD Great presentation overall though the intricate details pertaining to the data release still is imminent. They seem to have a plan in place to pull this through.

$IVVD Positive data could easily change things overnight once released, and off this goes to a whole new horizon.

$IVVD looks like it's setting itself up for a profitable pop, E.g. Institutional buy low, sell high. Typical pattern with this ticker.

$IVVD Invivyd Inc. (IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate. The study demonstrated that VYD2311 met primary and key secondary safety endpoints while enhancing antibody titers when combined with an mRNA vaccine.